Myome
MyOme is a clinical genomics company that uses whole-genome sequencing and proprietary Integrated Polygenic Risk Scores (iPRS™) to deliver proactive screening and rare-disease diagnostic tests to patients, providers, employers, and concierge clinics through its CLIA-certified Menlo Park laboratory and channel partnerships including Natera.
- Company typePrivate
- Founded2017
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Myome does
MyOme is a privately held, Menlo Park, California-based clinical genomics company founded in 2017 that operates a CLIA-certified, CAP-accredited laboratory performing whole-genome sequencing and a Blended Genome-Exome assay to deliver both proactive screening and rare-disease diagnostic tests ordered through a Provider Portal and Patient Portal. Its proactive health portfolio combines Single-Gene Risk panels, a Medication Response pharmacogenomic screen covering 70+ medications, and an Integrated Polygenic Risk Score (iPRS™) family for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer; its diagnostic portfolio includes Rare Disease Exome, Rare Disease Genome, and Rare Disease Copy Number Analysis, with optional trio/duo configurations, family variant testing, and re-queryable whole-genome data. The core technical differentiator is the proprietary iPRS methodology, which integrates millions of genetic variants with clinical risk factors such as ASCVD Pooled Cohort Equations and Tyrer-Cuzick and applies continuous ancestry decomposition to deliver risk estimates validated across diverse and mixed-ancestry cohorts (140,000+ individuals for prostate cancer, 150,000+ for breast cancer).
Revenue is generated on a pay-as-you-go basis via multiple streams: per-test diagnostic fees (CPT-coded 81415/81416, 81425/81426, 81349) billed through insurance, institutional contracts, self-pay, or financial assistance; bundled Proactive Health and Proactive Health Plus screening packages (FSA/HSA eligible); channel revenue from an exclusive partnership with Natera for the Zenith whole-genome rare-disease portfolio leveraging Natera's nationwide EMR-integrated clinical network; B2B distribution through employer benefits marketplaces (Thatch/ICHRA, Collective Health's The Partner Collective, Novi Health) and the Proactive Health Network of concierge, executive health, and longevity clinics; and follow-on Family Variant Testing and re-requisitions billed per variant from existing whole-genome data. Go-to-market spans direct-to-patient self-pay, provider-led ordering, channel partners, and employer/benefits-led distribution, with event-driven scientific marketing at ACMG, ASHG, ASCO, and ACC. The company is venture-backed (Sequoia, Foresite, HCVP, Founders Fund, Norwest, Alexandria, SoftBank, Duquesne, Natera) and received a strategic investment from Illumina in December 2025 alongside the MyOme Proactive Health (MPH) clinical trial launching enrollment in 2026.
Myome firmographics
Firmographics- Name
- Myome
- Legal name
- MyOme, Inc.
- Website
- https://myome.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MyOme is a clinical genomics company that uses whole-genome sequencing and proprietary Integrated Polygenic Risk Scores (iPRS™) to deliver proactive screening and rare-disease diagnostic tests to patients, providers, employers, and concierge clinics through its CLIA-certified Menlo Park laboratory and channel partnerships including Natera.
- Ownership category
- akta.pro rank
Myome industry classification
Industry- Product category
- Clinical Genomics / Genetic Testing Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Myome is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Myome business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Fees (Rare Disease Exome/Genome/CNV): Billed per test order with acceptable billing types including Insurance Coverage, Institutional, Self-Pay, and Financial Assistance (interest-free payment plans, income/family-based financial assistance, prompt-pay discounts). CPT-coded tests (e.g., 81415/81416 for exome, 81425/81426 for genome, 81349 for CNV).
- Proactive Health Screening Tests (Single-Gene Risk, Medication Response, iPRS): Screening tests sold to providers and through employer/benefits channels; patients can use FSA/HSA for screening tests. Offered as bundled Proactive Health and Proactive Health Plus packages or standalone iPRS tests, with flexible payment options.
- Channel Distribution Revenue via Natera (Zenith): Exclusive partnership with Natera for the Zenith whole-genome rare disease test portfolio; Natera leverages its nationwide EMR integration to scale distribution and MyOme participates in revenue from tests delivered through Natera's clinical network.
- B2B Employer/Benefits Channel Revenue: Distribution via benefits marketplaces such as Thatch (ICHRA), Collective Health's The Partner Collective, and Novi Health, plus the Proactive Health Network of concierge/executive clinics, providing genomic testing embedded in employer health programs and clinic memberships.
- Follow-up / Family Variant Testing Requisitions: Re-requisitions on existing whole-genome data and Family Variant Testing billed per variant tested (insurance or out-of-pocket); creates recurring engagement from the same patient/family without requiring a new sample.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance-billed diagnostic tests (Exome/Genome/CNV) |
| Other | Pay-as-you-go | Proactive Health and Proactive Health Plus screening packages |
| Unit Pricing | Pay-as-you-go | Family Variant Testing (per variant) |
Go-to-market motion6 records
Distribution channels6 records
Marketing channels7 records
Myome product offering
Product offeringCore offering
MyOme operates a clinical whole-genome sequencing platform that delivers proactive screening tests (Single-Gene Risk™, Medication Response™, and Integrated Polygenic Risk Score [iPRS™] tests for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer) and rare disease diagnostic tests (Rare Disease Genome, Exome, and Copy Number Analysis). All tests are processed at MyOme's CLIA-certified, CAP-accredited clinical laboratory in Menlo Park, CA, from a single patient sample, and are ordered through the MyOme Provider Portal or Patient Portal.
Product overview
Myome operates a unified clinical whole-genome testing platform that powers a portfolio of proactive screening and rare-disease diagnostic products ordered through the MyOme Provider Portal. The platform leverages 30x Whole Genome Sequencing (WGS) and Blended Genome-Exome Sequencing (BGE) to deliver the Proactive Health suite (Single-Gene Risk™, Medication Response™, and Integrated Polygenic Risk Score [iPRS™] tests for Coronary Artery Disease, Breast Cancer, Type 2 Diabetes, and Prostate Cancer) alongside the Diagnostic suite (Rare Disease Exome, Rare Disease Genome, and Rare Disease Copy Number Analysis), with Follow-up Testing (Requisitions and Family Variant Testing) extending insights from a single sample over time. The platform also underpins the MyOme Proactive Health Network for concierge and executive clinics, the Zenith™ rare-disease portfolio co-developed with Natera, and the MyOme Patient Portal for result access and education.
Differentiator
Problem solved
Functional benefit
Brands
- Proactive Health: MyOme's flagship portfolio of proactive genomic screening tests covering Single-Gene Risk, Medication Response, and Integrated Polygenic Risk Scores (iPRS) for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer.
- Integrated Polygenic Risk Score (iPRS)
- Proactive Health Network (PHN)
Products and services
- Proactive Health Test Suite
- Single-Gene Risk™
- Medication Response™
- Coronary Artery Disease iPRS™ (CAD iPRS)
- Breast Cancer iPRS™
- Type 2 Diabetes iPRS™ (T2D iPRS)
- Prostate Cancer iPRS™
- Rare Disease Exome Analysis
- Rare Disease Genome Analysis
- Rare Disease Copy Number Analysis
- Follow-up Testing (Requisitions and Family Variant Testing)
- Zenith™ Rare Disease Testing Portfolio (with Natera)
Quantifiable outcome
- Up to ~70% (T2D), ~60% (prostate cancer), and ~50% (CAD) of heritable disease risk can be detected as genetic markers by MyOme iPRS tests
- +8 more outcomes
Companies that use Myome
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles4 records
Myome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature7 records
Myome partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor, flagship and core.
- Start Genetic / CureSHANKminorMyOme is a supporting sponsor of the second annual Genetic Testing Action Day on July 25, 2026, an international awareness initiative operated by nonprofit CureSHANK and lead-sponsored by Illumina to raise awareness of genetic testing for rare diseases and developmental disabilities.
- NateraflagshipExclusive strategic partnership to develop and commercialize the Zenith whole-genome sequencing portfolio for rare disease diagnosis. The test uses long-read sequencing and was presented at the 2026 ACMG Annual Clinical Genetics Meeting. Natera leverages its nationwide EMR integration footprint to scale distribution of MyOme's genome-first diagnostic across the US, while also investing in MyOme's broader financing round.
- ThatchcoreEmbedded MyOme's genomics-based proactive health reports into Thatch's Personalized Benefits Marketplace, providing employer members easier access to predictive, preventative health insights. First genomics solution offered through Thatch's ICHRA platform.
- IlluminaflagshipCollaboration plus strategic investment from Illumina to support MyOme's Proactive Health (MPH) Trial, a large-scale prospective study starting enrollment in 2026 that will evaluate whole-genome sequencing combined with AI-integrated risk models for early detection of common, chronic conditions, cancers, and rare diseases. Illumina's sequencing technology roadmap (NovaSeq X) and continued backing are intended to accelerate MyOme's rare disease testing innovation and expand its commercially available products.
- Ms.MedicinecoreStrategic partnership to integrate MyOme's Proactive Health portfolio (monogenic disease screening, pharmacogenomic insights, polygenic risk scores) into Ms.Medicine's national network of women's health and concierge primary care practices. Tests delivered via Nest Genomics' clinical decision-support platform.
- Mayo Clinic PlatformcoreMyOme joined the Mayo Clinic Platform_Accelerate cohort, an initiative supporting healthcare innovators to validate and scale AI-based solutions using rich, de-identified clinical data sets to advance preventative care.
- Collective Health (The Partner Collective)coreMyOme joined The Partner Collective by Collective Health — a digital health partner hub that helps employers, brokers, and consultants discover and engage with innovative benefits offerings — to expand access to MyOme's whole-genome based products.
- Novi HealthcoreCollaboration to bring whole-genome sequencing, polygenic risk modeling, and personalized genetic counseling to employees as part of Novi Health's workplace health benefits, enabling participants to take preventative action against common and hereditary conditions.
- Southern ResearchcoreMulti-party initiative with Broad Clinical Labs and MyOme to bring MyOme's industry-leading clinical risk assessments free of charge to patients and providers in Alabama, empowering underserved communities with personalized genetic insights and potential life-saving interventions.
- Broad Clinical LabscoreSequencing technology partnership: Broad Clinical Labs deploys MyOme's bioinformatics and analysis pipeline on top of its advanced whole-genome sequencing technologies to deliver MyOme's individual risk assessments to clinics and patients.
- Arboretum BiominorQuoted partner endorsing MyOme's role in addressing long-standing biases in medicine and advancing precision medicine for diverse populations.
Scale indicators11 records
Recent moves6 records
Expansion highlights7 records
Myome competitors and assessment
Company assessmentDirect peers
- Ambry Genetics: Ambry Genetics (a Konica Minolta company) provides clinical exome and genome sequencing with a focus on rare-disease diagnosis and hereditary cancer. It competes directly with MyOme in the rare-disease diagnostic market and shares the CPT-coded clinical lab business model.
- Human Longevity Inc. Human Longevity offers whole-genome sequencing combined with advanced imaging and AI-driven preventive health assessments to executive and longevity-focused members. It is a direct peer to MyOme's Proactive Health Network and high-end proactive whole-genome testing positioning.
- Color Health: Color Health is a clinical genetics platform offering hereditary cancer screening, whole-genome sequencing, and employer-sponsored preventive genomics programs. It competes head-to-head with MyOme in the same employer/benefits and provider channels for preventive genetic testing.
- GeneDx: GeneDx is a clinical genomics company focused on rare-disease exome and genome sequencing for pediatric and neurological indications. It is a direct peer in MyOme's diagnostic rare-disease exome/genome/CNV offering, competing for the same ordering physicians and CPT-coded reimbursement.
- Invitae: Invitae is a clinical genetic testing company providing hereditary cancer, rare-disease, and reproductive health testing through providers and biopharma. It is a comparable peer across MyOme's diagnostic portfolio despite Invitae's recent financial restructuring.
- 23andMe: 23andMe is a consumer genetic testing company offering ancestry, trait, and health risk reports including polygenic risk scores. It is comparable in the direct-to-consumer and preventive health testing space and competes for similar consumer mindshare on genetic risk.
- Helix: Helix operates a clinical whole-genome sequencing platform that powers both rare-disease diagnostic and population-health applications via partner health systems. Like MyOme, Helix sells a re-queryable WGS backbone to providers, health systems, and consumer channels.
Broad incumbents
- Tempus: Tempus is an AI-driven precision medicine company combining multi-omics data with clinical records for oncology and beyond. It is a broader incumbent in genomics-enabled clinical decision support, with overlapping AI + clinical-data positioning versus MyOme's AI-integrated iPRS pipeline.
- Natera: Natera is a large, publicly traded cell-free DNA and reproductive health testing company that is also MyOme's exclusive Zenith distribution partner and investor. It is comparable in genetic testing scale and serves as both a partner and adjacent incumbent across reproductive, oncology, and rare-disease genomics.
Emerging players
- Genomic Prediction: Genomic Prediction develops and commercializes polygenic risk scores for disease risk assessment. It overlaps with MyOme's iPRS portfolio on the polygenic methodology but with a narrower set of conditions and a more research-oriented go-to-market.
Market position
Strengths6 records
Weaknesses6 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Myome social profiles
Digital presenceMyome compliance and trust
Trust signalCompliance4 records
Myome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Myome leadership team
Management profileNumber of profiles
Profiles19 records
Myome funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Myome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Myome
What does Myome do?
MyOme operates a clinical whole-genome sequencing platform that delivers proactive screening tests (Single-Gene Risk™, Medication Response™, and Integrated Polygenic Risk Score [iPRS™] tests for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer) and rare disease diagnostic tests (Rare Disease Genome, Exome, and Copy Number Analysis). All tests are processed at MyOme's CLIA-certified, CAP-accredited clinical laboratory in Menlo Park, CA, from a single patient sample, and are ordered through the MyOme Provider Portal or Patient Portal.
Is Myome a public or private company?
Myome is a private company. It is classified as venture growth investor backed and is currently operating.
When was Myome founded?
Myome was founded in 2017. It employs 11 to 50 people.
Where is Myome based?
Myome is headquartered in Palo Alto, United States, in the North America region.
How does Myome make money?
Five revenue lines are on record. Diagnostic Test Fees (Rare Disease Exome/Genome/CNV) is the primary driver. The others are proactive Health Screening Tests (Single-Gene Risk, Medication Response, iPRS), channel Distribution Revenue via Natera (Zenith), B2B Employer/Benefits Channel Revenue and follow-up / Family Variant Testing Requisitions.
Who are Myome's main competitors?
Direct peers on record are Ambry Genetics, Human Longevity Inc., Color Health, GeneDx, Invitae, 23andMe and Helix. Broad incumbents are Tempus and Natera. Genomic Prediction is listed as an emerging player.
Does Myome have an API?
No public API is recorded for Myome.
What industry is Myome in?
Myome's product category is Clinical Genomics / Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 8071.